Neoplasms

Blood and Lymph Conditions

All Conditions

Immune System Diseases

Symptoms and General Pathology

Heart and Blood Diseases

Behaviors and Mental Disorders

Rare Diseases

Leukemia

Lymphoma, Large B-Cell, Diffuse

Leukemia, Lymphoid

Lymphoma

Hematologic Neoplasms

Leukemia, Lymphocytic, Chronic, B-Cell

Lymphoma, Mantle-Cell

Lymphoma, Follicular

Lymphoma, B-Cell, Marginal Zone

Lymphoma, B-Cell

Waldenstrom Macroglobulinemia

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphoma, Non-Hodgkin

Hematologic Diseases

Leukemia, B-Cell

Chronic Disease

Disease Attributes

Neoplasms, Plasma Cell

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hemorrhagic Disorders

Quality of Life

B-cell Lymphoma

Diffuse Large B-Cell Lymphoma

Chronic Graft Versus Host Disease

Lymphosarcoma

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Follicular Lymphoma

Marginal Zone Lymphoma

Patients with CLL receiving systemic treatment (physician's choice)

Patients with DLBCL receiving systemic treatment (physician's choice)

Patients with FL receiving systemic treatment (physician's choice)

Patients with MCL receiving systemic treatment (physician's choice)

Patients with MZL receiving systemic treatment (physician's choice)

Patients with WM receiving systemic treatment (physician's choice)

Physician's choice according to patient's needs.

Routine care as per site standard.

Martina Jänicke, Dr.

Rainer Claus, Prof. Dr.

Tobias Dechow

Paul Graf La Rosée, Prof. Dr.

Jens Kisro, Dr.

Patrick Marschner, Dr.

Ingo Tamm, PD Dr.

Robert Zeiser, Prof. Dr.

The purpose of the project is to set up a national, prospective, longitudinal, multicenter registry platform to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with hematological malignancies in Germany.

RUBIN is a national, observational, prospective, longitudinal, multicenter registry platform with the purpose to record information on the antineoplastic treatment of hematological malignancies in Germany.

It will identify common therapeutic sequences and changes in the treatment of the disease, and will analyse the impact of novel treatments on the outcome of patients in routine care. Unmet needs and areas with the potential for improvement in routine care are to be identified.

At inclusion, data in patient characteristics, comorbidities, clinical characteristics and previous treatments, if applicable, are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and clinical outcome are documented.

Health-realted quality of life in patients with hematological malignancies will be evaluated for up to one year.

Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms

Clinical Research Platform on Treatment, Quality of Life and Outcome of Patients With Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms

Documentation of anamnestic data and therapy sequences. Documentation of anamnestic data and therapy sequences

Documentation of response rates per line of treatment.

Documentation of progression-free survival per line of treatment.

iOMEDICO AG

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Carcinoma

Carcinoma, Renal Cell

Carcinoma, Transitional Cell

Urologic Neoplasms

Neoplasms, Glandular and Epithelial

Adenocarcinoma

Kidney Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Diseases

Urologic Diseases

Male Urogenital Diseases

Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

Transitional Cell Carcinoma

Patients with advanced renal cell carcinoma

Patients with advanced urothelial carcinoma

Michaela Koska

Michael Staehler, Prof. Dr.

Peter Goebell, Prof. Dr.

Lothar Müller, Dr.

Viktor Grünwald, Prof. Dr.

Carsten Grüllich, Prof. Dr.

Christian Gratzke, Prof. Dr.

The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with advanced renal cell carcinoma or advanced urothelial cancer in Germany.

CARAT is a national, observational, prospective, longitudinal, multicenter cohort study (tumor registry platform) with the purpose to record information on the antineoplastic treatment of renal cell carcinoma and urothelial cancer in Germany. The registry will follow patients with advanced renal carcinoma for up to three years, and patients with advanced urothelial cancer for up to two years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented.

Health-related quality of life (HRQoL) in patients with renal cell carcinoma or urothelial cancel will be evaluated for up to two years.

Registry Platform Urologic Cancer

Clinical Research Platform On Urologic Cancer Treatment And Outcome (Registry Platform Urologic Cancer; CARAT)

Documentation of anamnestic data and therapy sequences

Cohort aRCC: National Comprehensive Cancer Network/ Functional Assessment of Cancer Therapy (FACT)-Kidney Symptom Index 19 (NCCN-FACT FKSI-19) Cohort aUBC: NCCN/FACT Bladder Symptom Index (NCCN-FACT FBlSI-18, Version 2)

Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™) - Items/Scores cohort aRCC: 3/7/15/22/24/27/28/50/51; Items/Scores cohort aUBC: 3/7/15/22/24/27/28/39/45/50/51

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms	NCT06043011	Chronic Lymphoc... Diffuse Large B... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Waldenström's M...	Routine care as...	18 Years -	iOMEDICO AG
Registry Platform Urologic Cancer	NCT03374267	Renal Cell Carc... Urothelial Carc...	Routine care as...	18 Years -	iOMEDICO AG
Registry Platform Urologic Cancer	NCT03374267	Renal Cell Carc... Urothelial Carc...	Routine care as...	18 Years -	iOMEDICO AG

Spots Global Cancer Trial Database for routine care as per site standard.